Inclusion Criteria:

          -  Clear evidence of metastases to bone on isotope bone scan

          -  Histologically or cytologically confirmed metastatic Estrogen-receptor-positive (ER+)
             and/or Progesterone-receptor-positive (PR+) and Human Epidermal Growth Factor Receptor
             (HER) 2 negative breast cancer

          -  Received at least one prior line of hormonal or chemo-therapy for metastatic disease

          -  must be post menopausal

          -  Recovered from toxicities related to prior treatment, except alopecia, lymphopenia, or
             other non-clinically significant Adverse Events (AEs)

          -  Life expectancy > 3 months

          -  Adequate organ and marrow function

          -  Sexually active fertile subjects and their partners must agree to use medically
             accepted methods of contraception

          -  Able to lie flat for up to 45 minutes for imaging studies

          -  Able to swallow capsules or tablets

        Exclusion Criteria:

          -  Pregnant or breast-feeding

          -  Has experienced clinically-significant hematemesis or hemoptysis of > 0.5 teaspoons of
             red blood, or other signs indicative of pulmonary hemorrhage within 3 months before
             the first dose of study treatment

          -  Untreated, symptomatic or uncontrolled brain metastasis requiring current treatment
             including steroids and anti-convulsants

          -  more than 1 prior line of chemotherapy for treatment of metastatic breast cancer

          -  prior treatment with fulvestrant

          -  Requires concomitant treatment, in therapeutic doses, with anticoagulants such as
             warfarin or coumadin-related agents, thrombin or Factor Xa inhibitors, and
             antiplatelet agents (eg, clopidogrel)

          -  Uncontrolled or significant intercurrent illness

          -  Gastrointestinal disorders, particularly those associated with a high risk of
             perforation or fistula formation

          -  Active infection requiring systemic treatment

          -  Serious non-healing wound/ulcer/bone fracture

          -  History of organ transplant

          -  Concurrent uncompensated hypothyroidism or thyroid dysfunction

          -  Previously-identified allergy or hypersensitivity to components of the study treatment
             formulation

          -  Diagnosis of another malignancy, requiring systemic treatment, within the last 2
             years, unless non-melanoma skin cancer, in-situ carcinoma of the cervix, or
             superficial bladder cancer